The genetics and pathogenesis of haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura
- 1 July 2002
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 11 (4) , 431-435
- https://doi.org/10.1097/00041552-200207000-00010
Abstract
In recent years there has been a substantial increase in the understanding of the genetics and pathogenesis of haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. In diarrhoeal associated haemolytic uraemic syndrome it has been established that the virulence of Escherichia coli O157 is related to intimin adhesion and the transport of verocytotoxin on polymorphonuclear cells. It has been shown that early changes in the coagulation pathway predate the onset of diarrhoeal haemolytic uraemic syndrome. Mutations in factor H, a fluid-phase regulator of the alternative complement pathway, have been identified in 10-20% of patients with both familial and sporadic (non-diarrhoeal-associated) haemolytic uraemic syndrome. The mutations mainly cluster in the C terminal part of factor H, a region that is important for both binding to C3b and also polyanionic structures on cell surfaces. The identification of antibodies against a plasma metalloproteinase responsible for cleaving ultralarge von Willebrand factor multimers in thrombotic thrombocytopenic purpura has been followed by the elucidation of the identity of the proteinase. It has been shown to be a member of the ADAMTS family, and mutations have been identfied in the gene in families with inherited thrombotic thrombocytopenic purpura. The molecular pathogenesis of haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura is an exciting and rapidly evolving field. These recent advances will lead to logical, targetted changes in the management of these conditions.Keywords
This publication has 45 references indexed in Scilit:
- Molecular modelling of the C-terminal domains of factor H of human complement: a correlation between haemolytic uraemic syndrome and a predicted heparin binding siteJournal of Molecular Biology, 2002
- Response to Shiga Toxin-1, with and without Lipopolysaccharide, in a Primate Model of Hemolytic Uremic SyndromeAmerican Journal of Nephrology, 2001
- Endothelial Cell Apoptotic Genes Associated with the Pathogenesis of Thrombotic Microangiopathies: An Application of Oligonucleotide Genechip TechnologyMicrovascular Research, 2001
- Vero Cytotoxin Binding to Polymorphonuclear Leukocytes among Households with Children with Hemolytic Uremic SyndromeThe Journal of Infectious Diseases, 2001
- Folded-back solution structure of monomeric factor H of human complement by synchrotron X-ray and neutron scattering, analytical ultracentrifugation and constrained molecular modellingJournal of Molecular Biology, 2001
- Factor H Mutations in Hemolytic Uremic Syndrome Cluster in Exons 18–20, a Domain Important for Host Cell RecognitionAmerican Journal of Human Genetics, 2001
- Clustering of Missense Mutations in the C-Terminal Region of Factor H in Atypical Hemolytic Uremic SyndromeAmerican Journal of Human Genetics, 2001
- Each of the Three Binding Sites on Complement Factor H Interacts with a Distinct Site on C3bJournal of Biological Chemistry, 2000
- Complement Factor H Gene Mutation Associated with Autosomal Recessive Atypical Hemolytic Uremic SyndromeAmerican Journal of Human Genetics, 2000
- Complement Factor H Gene Mutation Associated with Autosomal Recessive Atypical Hemolytic Uremic SyndromeAmerican Journal of Human Genetics, 1999